- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immunome Inc (IMNM)
The Immunome share price today is 19.10, view NASDAQ IMNM stock exchange data. Track the latest Immunome share price with real-time updates on IMNM stock performance including market cap, day range, 52-week range and dividend yield. Access IMNM charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.94
19.56
52 wk Range
13.49
30.06
IMNM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.9419.56
52 wk Range
13.4930.06
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMNM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
35.20
Upside
+84.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
15 Buy
1 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 35.20
(+84.29% Upside)
Earnings
Latest Release
11-08-2026
EPS / Forecast
-0.65 / -0.51
Revenue / Forecast
-- / 181.82K
Compare IMNM to Peers and Sector
Metrics to compare | IMNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.5x | −2.2x | −0.3x | |
PEG Ratio | −0.56 | −0.06 | 0.00 | |
Price/Book | 4.1x | 3.5x | 2.6x | |
Price / LTM Sales | - | 62.4x | 3.0x | |
Upside (Analyst Target) | 82.3% | 53.7% | 58.2% | |
Fair Value Upside | Unlock | 10.8% | 7.5% | Unlock |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Immunome (IMNM) Share Price Today?
The Immunome share price today is 19.10.
What is the current Immunome (IMNM) share price and day range?
As of 07-10-2026, the Immunome share price is 19.10, with a previous close of 19.31. The share price has ranged from 18.94 to 19.56 today, while the 52-week range spans from 13.49 to 30.06.
What Is the Immunome Market Cap?
As of today, Immunome market cap is 2.18B.
What Is the Immunome (IMNM) Share Price Target?
The average 12-month share price target for Immunome is 35.20, with a high estimate of 40 and a low estimate of 24. 15 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +84.29% Upside potential.
What Is Immunome's Earnings Per Share (TTM)?
The Immunome EPS (TTM) is -2.49.
When Is the Next Immunome Earnings Date?
Immunome will release its next earnings report on 16-11-2026.
From a Technical Analysis Perspective, Is IMNM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Immunome Trade On?
Immunome is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immunome?
The stock symbol for Immunome is "IMNM."
How Many Times Has Immunome Stock Split?
Immunome has split 0 times.
How Many Employees Does Immunome Have?
Immunome has 247 employees.
What Is the IMNM Premarket Price?
IMNM's last pre-market stock price is 19.15. The pre-market share volume is 1,870.00, and the stock has changed by -0.16, or -0.83%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.